Madison pharmaceutical technology company Invenra has raised another $3 million from 27 investors, according to a filing with securities regulators Wednesday.

Invenra has a proprietary platform that allows for rapid screening of potential new drug candidates without using living cells.

The new money will be used for “research and development and general corporate purposes,” the company said in the filing. Read the full Journal Sentinel article here.